Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB414 in mild to moderate atopic dermatitis
NCT03431610Phase 1Completed
- Sponsor
- Novan
- Start
- Nov 2017
- Primary completion
- May 2018
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of berdazimer in atopic dermatitis (AD) (3 arms), sponsored by Novan. Primary endpoint: Plasma concentrations of hMAP3 at Day 15. Started Nov 2017; status: completed.
02
Drugs
berdazimer
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03431610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431610.